Author pages are created from data sourced from our academic publisher partnerships and public sources.
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
- J. Strosberg, G. El-Haddad, +32 authors E. Krenning
- The New England journal of medicine
- 11 January 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first‐line somatostatin analogue therapy have limited therapeutic options. This randomized,… Expand
Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well‐Differentiated Disease
&NA; Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs and… Expand
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
- S. Hingorani, L. Zheng, +16 authors A. Hendifar
- Journal of clinical oncology : official journal…
- 12 December 2017
Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by excessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure and impairing perfusion.… Expand
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
- Oliver A. Zill, Claire Greene, +14 authors E. Collisson
- Biology, Medicine
- Cancer discovery
- 1 October 2015
UNLABELLED Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA)… Expand
A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era
Four decades ago, specialized chemotherapy regimens turned osteosarcoma, once considered a uniformly fatal disease, into a disease in which a majority of patients survive. Though significant survival… Expand
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
- G. Lurje, W. Zhang, +8 authors H. Lenz
- Annals of oncology : official journal of the…
- 1 October 2008
BACKGROUND Identifying molecular markers for tumor recurrence is critical in successfully selecting patients with stage III colon cancer who are more likely to benefit from adjuvant chemotherapy. The… Expand
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Importance KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathways… Expand
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity.
BACKGROUND Despite the success of modern chemotherapy in the treatment of large bowel cancers, patients with metastatic gastric cancer continue to have a dismal outcome. Identifying predictive and… Expand
Pancreatic cancer cachexia: a review of mechanisms and therapeutics
Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge. Pancreatic… Expand
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
AIM This randomised phase III trial evaluated first-line trabectedin versus doxorubicin-based chemotherapy (DXCT) in patients with advanced/metastatic translocation-related sarcomas (TRS). METHODS… Expand